On April 21, 2020 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that it will release its financial results for the quarter ended March 31, 2020, on Tuesday, May 5, 2020, after the close of the market (Press release, Aptose Biosciences, APR 21, 2020, View Source [SID1234556456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast:

Date: Tuesday, May 5, 2020
Time: 5:00 PM Eastern Time
Dial In – Toll-Free: 1 844-882-7834
Dial In – International: 1 574-990-9707
Passcode: 6470926
Webcast: LINK

Replay available through May 19, 2020:

Dial In – Toll-Free: 1 855-859-2056
Dial In – International: 1 404-537-3406
Replay Passcode: 6470926
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at View Source An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the quarter ended March 31, 2020 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.